AGÕæÈ˹ٷ½

STOCK TITAN

Praxis Precision Medicines, Inc. SEC Filings

PRAX NASDAQ

Welcome to our dedicated page for Praxis Precision Medicines SEC filings (Ticker: PRAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Reading Praxis Precision Medicines� dense clinical disclosures can feel like navigating ion-channel schematics after midnight. Each 8-K on trial data, every 300-page 10-K, and the constant trickle of Form 4s paint a moving picture of pipeline risk and cash needs—but only if you find the right line items. That’s the problem.

Stock Titan solves it. Our platform ingests every Praxis Precision Medicines quarterly earnings report 10-Q filing, real-time Praxis Precision Medicines Form 4 insider transactions, and each sudden 8-K material event, then delivers AI-powered summaries that explain what changed—in language as clear as your morning coffee. Search “What does Praxis report in its SEC filings?� or “How to read Praxis Precision Medicines� 10-K annual report� and arrive here: insider trading Form 4 alerts, segment spending breakdowns, and liquidity updates all mapped to the company’s Cerebrum� and Solidus� programs.

Inside the feed you’ll find:

  • Praxis Precision Medicines insider trading Form 4 transactions with context on clinical catalysts
  • Praxis Precision Medicines annual report 10-K simplified into key risk factors and cash runway metrics
  • Praxis Precision Medicines proxy statement executive compensation cross-linked to R&D milestones
  • Praxis Precision Medicines quarterly earnings report 10-Q filing trend graphs and AI commentary
  • Praxis Precision Medicines 8-K material events explained against trial timelines

Whether you’re comparing burn rate quarter-over-quarter, tracking executive stock transactions Form 4, or simply understanding Praxis Precision Medicines SEC documents with AI, our continuously updated dashboard keeps you ahead of the next clinical readout—without combing through endless PDFs.

Rhea-AI Summary

Adage Capital Management, L.P. reported an initial Section 16 filing for Praxis Precision Medicines, Inc. (PRAX) disclosing 2,374,085 shares beneficially owned indirectly. The filing states these shares are held directly by Adage Capital Partners, L.P. (ACP) and that Adage Capital Management, L.P. (ACM) serves as ACP's investment manager with discretionary authority over the portfolio. Robert Atchinson and Phillip Gross are identified as managing members of related Adage entities. The reporting persons are listed as Directors and as a 10% owner relationship to the issuer. The filing includes standard Section 16 disclaimers that each reporting person disclaims beneficial ownership except for any pecuniary interest, and it is signed by Adage and the two individuals on 08/19/2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Point72-associated entities and Steven A. Cohen report collective beneficial ownership of Praxis Precision Medicines (PRAX) common stock totaling 1,531,038 shares, representing 7.3% of the outstanding class as of June 30, 2025. The filing shows 1,465,105 shares reported by Point72 Asset Management/Point72 Capital Advisors (7.0%) and 65,933 shares held by related entities (0.3%). The total includes 511,030 shares issuable upon exercise of warrants, which are counted in the denominator used for the percent calculation. The report states these holdings are not intended to change or influence control of the issuer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
-
Rhea-AI Summary

Cormorant Asset Management, LP and Bihua Chen report beneficial ownership of 1,625,000 shares of Praxis Precision Medicines common stock, representing 7.72% of the outstanding class. The shares are held through Cormorant-managed funds (the "Cormorant Funds") and the filing attributes voting and dispositive authority as shared rather than sole power.

The filing notes that the Cormorant Funds have the economic rights to dividends or sale proceeds and identifies Cormorant Global Healthcare Master Fund, LP as a fund with rights to more than 5% of the reported shares. The statement clarifies it is filed on behalf of both reporting persons and disclaims that the filing alone establishes beneficial ownership for purposes of Section 13.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
Rhea-AI Summary

This amendment to a Schedule 13G reports that Janus Henderson Group plc and an affiliated fund hold material stakes in Praxis Precision Medicines common stock. The filing shows Janus Henderson Group plc beneficially owns 2,533,405 shares, representing 12.4% of the class, with shared voting and dispositive power over those shares. Janus Henderson Biotech Innovation Master Fund Ltd is reported to beneficially own 1,186,586 shares ( 5.8% ).

The filing identifies indirect subsidiaries (JHIUS, JHIUKL and JHIAIFML) as registered investment advisers and includes a certification that the securities were acquired in the ordinary course of business and not for the purpose of changing or influencing control. A power of attorney authorizes certain compliance officers to file and amend reporting documents on behalf of Janus Henderson.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
-
Rhea-AI Summary

Adage Capital Management, L.P., together with Robert Atchinson and Phillip Gross, report beneficial ownership of 1,974,585 shares of Praxis Precision Medicines common stock, representing 9.69% of the outstanding class. The shares are directly held by Adage Capital Partners, L.P. and the percentage is calculated using an aggregate of 20,368,982 shares outstanding as reported by the company.

The filing shows shared voting and shared dispositive power for the reporting persons and no sole voting or dispositive power. It also certifies the securities are held in the ordinary course of business and were not acquired to change or influence control of the issuer. Reporting entities are organized in Delaware and the named individuals are U.S. citizens.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.69%
Tags
other
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.55%
Tags
current report
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.55%
Tags
quarterly report
-
Rhea-AI Summary

Perceptive Advisors LLC, its Perceptive Life Sciences Master Fund, Ltd. and founder Joseph Edelman have filed a Schedule 13G disclosing a passive stake in Praxis Precision Medicines (PRAX).

  • Shares owned: 1,362,503 common shares.
  • Ownership percentage: 6.69 % of the 20,368,982 shares outstanding as of 30 Apr 2025.
  • Control rights: The Reporting Persons hold shared voting and dispositive power over all shares; they report zero sole voting/dispositive power, indicating no unilateral control.
  • Date of event: 15 Jul 2025; filing signed 22 Jul 2025.
  • Filer status: Perceptive Advisors is an investment adviser (IA); Edelman is a U.S. individual; Master Fund is Cayman-based.

The certification states the securities were not acquired to influence control, confirming a passive investment posture. Perceptive’s >5 % position may draw investor attention because the healthcare-focused fund is considered a sophisticated life-sciences investor.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.44%
Tags
current report

FAQ

What is the current stock price of Praxis Precision Medicines (PRAX)?

The current stock price of Praxis Precision Medicines (PRAX) is $47.9 as of August 26, 2025.

What is the market cap of Praxis Precision Medicines (PRAX)?

The market cap of Praxis Precision Medicines (PRAX) is approximately 987.9M.
Praxis Precision Medicines, Inc.

NASDAQ:PRAX

PRAX Rankings

PRAX Stock Data

987.89M
19.64M
0.16%
118.59%
10.08%
Biotechnology
Pharmaceutical Preparations
United States
BOSTON